Gotham Asset Management LLC Sells 5,047 Shares of Gilead Sciences, Inc. $GILD

Key Points

• Gotham Asset Management LLC reduced its holdings in Gilead Sciences, Inc. by 2.0%, now owning 250,994 shares worth approximately $28.1 million.
• Several research analysts have raised their price targets for Gilead Sciences, with Truist Financial increasing their target from $108 to $127, and a consensus price target now set at $115.39.
• Gilead Sciences recently declared a quarterly dividend of $0.79 per share, with a yield of 2.8%, to be paid on September 29th.

Gotham Asset Management LLC lowered its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 2.0% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 250,994 shares of the biopharmaceutical company's stock after selling 5,047 shares during the period. Gilead Sciences accounts for 0.2% of Gotham Asset Management LLC's portfolio, making the stock its 29th largest position. Gotham Asset Management LLC's holdings in Gilead Sciences were worth $28,124,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Price T Rowe Associates Inc. MD grew its holdings in Gilead Sciences by 314.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company's stock worth $1,647,484,000 after acquiring an additional 11,156,382 shares during the period. Nuveen LLC acquired a new stake in Gilead Sciences during the 1st quarter worth $620,415,000. GAMMA Investing LLC grew its holdings in Gilead Sciences by 13,891.1% during the 1st quarter. GAMMA Investing LLC now owns 2,550,298 shares of the biopharmaceutical company's stock worth $285,761,000 after acquiring an additional 2,532,070 shares during the period. Los Angeles Capital Management LLC grew its holdings in Gilead Sciences by 422.6% during the 1st quarter. Los Angeles Capital Management LLC now owns 2,523,036 shares of the biopharmaceutical company's stock worth $282,706,000 after acquiring an additional 2,040,261 shares during the period. Finally, Royal Bank of Canada grew its holdings in Gilead Sciences by 30.1% during the 4th quarter. Royal Bank of Canada now owns 8,678,751 shares of the biopharmaceutical company's stock worth $801,655,000 after acquiring an additional 2,005,863 shares during the period. Institutional investors and hedge funds own 83.67% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have commented on GILD shares. Truist Financial raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and lifted their target price for the stock from $108.00 to $127.00 in a report on Friday, August 8th. Needham & Company LLC raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 target price for the company in a report on Friday, July 25th. Royal Bank Of Canada lifted their target price on shares of Gilead Sciences from $96.00 to $98.00 and gave the stock a "sector perform" rating in a report on Friday, August 8th. Daiwa Capital Markets raised shares of Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 target price for the company in a report on Tuesday, August 19th. Finally, UBS Group lifted their target price on shares of Gilead Sciences from $108.00 to $112.00 and gave the stock a "neutral" rating in a report on Friday, August 8th. Three investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $115.39.

Insider Buying and Selling at Gilead Sciences

In related news, Director Jeffrey Bluestone sold 5,000 shares of the stock in a transaction that occurred on Monday, July 14th. The shares were sold at an average price of $109.74, for a total transaction of $548,700.00. Following the sale, the director owned 8,920 shares in the company, valued at approximately $978,880.80. This trade represents a 35.92% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Johanna Mercier sold 28,000 shares of the stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $118.53, for a total transaction of $3,318,840.00. Following the sale, the insider owned 114,168 shares in the company, valued at $13,532,333.04. This represents a 19.70% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 82,000 shares of company stock worth $9,371,330. 0.27% of the stock is currently owned by company insiders.

Gilead Sciences Stock Performance

Shares of GILD stock traded down $0.12 on Tuesday, reaching $115.76. The stock had a trading volume of 5,243,133 shares, compared to its average volume of 8,131,320. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13. The firm's 50-day moving average is $113.69 and its two-hundred day moving average is $109.95. The firm has a market capitalization of $143.64 billion, a price-to-earnings ratio of 23.06, a P/E/G ratio of 0.78 and a beta of 0.36. Gilead Sciences, Inc. has a 12 month low of $78.73 and a 12 month high of $121.83.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.96 by $0.05. The company had revenue of $7.08 billion for the quarter, compared to analysts' expectations of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. Gilead Sciences's quarterly revenue was up 1.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, research analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, September 29th. Shareholders of record on Monday, September 15th will be given a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date is Monday, September 15th. Gilead Sciences's dividend payout ratio is presently 62.95%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.